Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ANGIODYNAMICS INC

Get SEC filing alerts via email and in your feed for ANGIODYNAMICS INC

ANGO

ANGIODYNAMICS INC

About ANGIODYNAMICS INC

AngioDynamics, Inc. is a diversified medical technology company focused on enhancing treatment options for cardiovascular diseases and cancer. Its key products include the Auryon Atherectomy System and various thrombus management devices. With a growing market opportunity, AngioDynamics targets interventional radiologists and oncologists. The company emphasizes innovation through R&D and strategic acquisitions, aiming to improve patient outcomes and expand its product offerings in the competitive medical device landscape.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ANGIODYNAMICS INC

1
1
ANGIODYNAMICS INC AngioDynamics Reports $8.1 Million Net Loss and 8.9% Revenue Growth for Quarter Ended February 28, 2026

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
ANGIODYNAMICS INC AngioDynamics Reports 9% Revenue Growth and Reduced Net Loss in Q2 Fiscal 2026

Via official filing (AI summary) | 5 months ago | 0 comments

3
1
ANGIODYNAMICS INC AngioDynamics Reports $10.9M Net Loss and 12.2% Revenue Growth in Q1 FY 2026

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
ANGIODYNAMICS INC AngioDynamics Reports $292.5 Million Revenue, Net Loss Improvement in Fiscal Year Ending May 31, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
ANGIODYNAMICS INC AngioDynamics Reports Revenue Decline and Reduced Net Loss in Q3 Fiscal 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ANGIODYNAMICS INC AngioDynamics Reports 7.9% Decline in Q2 Revenue, Net Loss Improves

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ANGIODYNAMICS INC AngioDynamics Reports Significant Decline in Financial Performance for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments